<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="oca4" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">oca4</book-part-id>
      <title-group>
        <title>Oculocutaneous Albinism Type 4</title>
        <alt-title alt-title-type="alt-title">Synonym: OCA4</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hayashi</surname>
            <given-names>Masahiro</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="oca4.Tc.aff1"/>
          <email>czk11223@nifty.ne.jp</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Suzuki</surname>
            <given-names>Tamio</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="oca4.Tc.aff1"/>
          <email>tamsuz@med.id.yamagata-u.ac.jp</email>
        </contrib>
      </contrib-group>
      <aff id="oca4.Tc.aff1">Department of Dermatology<break/>Faculty of Medicine<break/>Yamagata University<break/>Yamagata, Japan</aff>
      <pub-history>
        <date date-type="created">
          <day>17</day>
          <month>11</month>
          <year>2005</year>
        </date>
        <date date-type="updated">
          <day>7</day>
          <month>9</month>
          <year>2017</year>
        </date>
        <date date-type="revised">
          <day>15</day>
          <month>9</month>
          <year>2011</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="oca2" document-type="chapter">Oculocutaneous Albinism Type 2</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="opmd" document-type="chapter">Oculopharyngeal Muscular Dystrophy</related-object>
      <abstract id="oca4.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Oculocutaneous albinism type 4 (OCA4) is characterized by hypopigmentation of the hair and skin plus the characteristic ocular changes found in all other types of albinism, including: nystagmus; reduced iris pigment with iris translucency; reduced retinal pigment with visualization of the choroidal blood vessels on ophthalmoscopic examination; foveal hypoplasia associated with reduction in visual acuity; and misrouting of the optic nerves at the chiasm associated with alternating strabismus, reduced stereoscopic vision, and an altered visual evoked potential (VEP). Individuals with OCA4 are usually recognized within the first year of life because of hypopigmentation of the hair and skin and the ocular features of nystagmus and strabismus. Vision is likely to be stable after early childhood. The amount of cutaneous pigmentation in OCA4 ranges from minimal to near normal. Newborns with OCA4 usually have some pigment in their hair, with color ranging from silvery white to light yellow. Hair color may darken with time, but does not vary significantly from childhood to adulthood.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Because the phenotype of OCA4 overlaps that of the other genetic forms of albinism (oculocutaneous and ocular), the diagnosis of OCA4 is established by molecular genetic testing with the identification of biallelic pathogenic variants in <italic toggle="yes">SLC45A2</italic>. A multi-gene panel or comprehensive genome sequencing is the preferred molecular genetic testing method for this disorder.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Correction of refractive errors with spectacles or contact lenses to improve visual acuity. Strabismus surgery may be considered for cosmetic reasons. Dark glasses may alleviate photophobia but may reduce vision; a hat with a brim or visor best achieves reduction in photophobia. Protection from the sun, through the wearing of protective clothing and the regular application of sunscreen, is essential.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Individuals with OCA4 should stay out of the sun from an early age, because cumulative ultraviolet exposure is a major risk factor for skin cancers.</p>
          <p><italic toggle="yes">Surveillance:</italic> Annual ophthalmologic examination and reassessment for accurate correction of refractive error. Evaluation of the skin for cancer screening every six months is recommended.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Prolonged exposure to sun.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>OCA4 is typically inherited in an autosomal recessive manner. The parents of a proband are obligate heterozygotes and thus carriers of one <italic toggle="yes">SLC45A2</italic> pathogenic variant. Heterozygotes (carriers) are asymptomatic and not at risk of developing the disorder, but may be light in pigmentation for their ethnic group. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="oca4.Diagnosis">
        <title>Diagnosis</title>
        <sec id="oca4.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Oculocutaneous albinism type 4 (OCA4) <bold>should be suspected</bold> in individuals with the following clinical features:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Hypopigmentation</bold> of the skin and hair varying from complete depigmentation to partial depigmentation with brown hair. In some individuals pigmentation increases during the first decade of life [<xref ref-type="bibr" rid="oca4.REF.suzuki.2008.1">Suzuki &#x00026; Tomita 2008</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Characteristic ocular changes</bold> found in all types of albinism, including the following findings detected on routine ophthalmologic examination:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Nystagmus</p>
                </list-item>
                <list-item>
                  <p>Reduced iris pigment with iris translucency</p>
                </list-item>
                <list-item>
                  <p>Reduced retinal pigment with visualization of the choroidal blood vessels on ophthalmoscopic examination</p>
                </list-item>
                <list-item>
                  <p>Foveal hypoplasia associated with reduction in visual acuity</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Vision abnormalities</bold> (due to misrouting of the optic nerves at the chiasm) including:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Alternating strabismus</p>
                </list-item>
                <list-item>
                  <p>Reduced stereoscopic vision</p>
                </list-item>
                <list-item>
                  <p>Altered visual evoked potential (VEP)</p>
                  <p>Note: (1) A VEP is not necessary for the routine diagnosis of albinism; misrouting is implied by the finding of strabismus and reduced stereoscopic vision. (2) In some individuals, particularly those who have moderate amounts of cutaneous and retinal pigment, or those who have foveal hypoplasia and no obvious nystagmus, a VEP may be necessary to demonstrate misrouting of the optic nerves. (3) The VEP is performed with a technique specifically developed for demonstration of the misrouting and a regular VEP will not demonstrate this. (4) Normal routing of the optic nerves, demonstrated with a VEP, indicates that the diagnosis is not albinism/OCA.</p>
                </list-item>
              </list>
            </list-item>
          </list>
        </sec>
        <sec id="oca4.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of OCA4 <bold>is established</bold> in a proband with characteristic clinical findings and/or by identification of biallelic pathogenic variants in <italic toggle="yes">SLC45A2</italic> on molecular genetic testing (see <xref ref-type="table" rid="oca4.T.molecular_genetic_testing_used_in">Table 1</xref>).</p>
          <p>Molecular genetic testing approaches can include the use of a <bold>multi-gene panel</bold> or <bold>comprehensive genome sequencing</bold>.</p>
          <p>Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing does not. Because the phenotype of OCA4 overlaps that of the other genetic forms of albinism (oculocutaneous and ocular), a multi-gene panel or comprehensive genome sequencing (when available) is the preferred molecular genetic testing method for this disorder. Single-gene testing (sequence analysis of <italic toggle="yes">SLC45A2,</italic> followed by gene-targeted deletion/duplication analysis) is rarely useful and typically NOT recommended.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">SLC45A2</italic> and other genes of interest associated with albinism (see <xref ref-type="sec" rid="oca4.Differential_Diagnosis">Differential Diagnosis</xref>) may be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene varies by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of condition at the most reasonable cost while limiting identification of pathogenic variants in genes that do not explain the underlying phenotype. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.</p>
              <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
            </list-item>
            <list-item>
              <p><bold>Comprehensive genome sequencing</bold> (when available) including exome sequencing and genome sequencing may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation).</p>
              <p>For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <p>For this disorder a multi-gene panel that also includes deletion/duplication analysis or exome array is recommended if no or only one pathogenic variant is identified.</p>
          <table-wrap id="oca4.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in OCA4</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">SLC45A2</italic>
                  </td>
                  <td headers="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">75%-85%&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Rare&#x000a0;<sup>6</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="oca4.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="oca4" object-id="oca4.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="oca4.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="oca4.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
              </fn>
              <fn id="oca4.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="oca4.TF.1.4">
                <label>4. </label>
                <p><xref ref-type="bibr" rid="oca4.REF.inagaki.2004.466">Inagaki et al [2004]</xref>, <xref ref-type="bibr" rid="oca4.REF.sengupta.2007.1406">Sengupta et al [2007]</xref>, <xref ref-type="bibr" rid="oca4.REF.hutton.2008.2442">Hutton &#x00026; Spritz [2008]</xref>, <xref ref-type="bibr" rid="oca4.REF.wei.2011.124">Wei et al [2011]</xref>, <xref ref-type="bibr" rid="oca4.REF.mauri.2017.277">Mauri et al [2017]</xref></p>
              </fn>
              <fn id="oca4.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="oca4.TF.1.6">
                <label>6. </label>
                <p><xref ref-type="bibr" rid="oca4.REF.rooryck.2008.583">Rooryck et al [2008]</xref> identified deletion of exon 4 in <italic toggle="yes">SLC45A2</italic> in an individual who was described as having a severe phenotype at birth which became milder with age.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>Note: <xref ref-type="bibr" rid="oca4.REF.oki.2017.1008">Oki et al [2017]</xref> reported a multigenerational family in which OCA4 appeared to be inherited as an autosomal dominant condition associated with a heterozygous pathogenic variant in <italic toggle="yes">SLC45A2</italic>. The authors of this <italic toggle="yes">GeneReview</italic> feel that this may represent a rare occurrence, but note that no functional assay for the specific variant was performed and that concomitant heterozygous pathogenic variant(s) in a regulatory region or in other (unknown) OCA-related genes cannot be ruled out.</p>
          <p><bold>Test characteristics.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/v22/n8/full/ejhg2013307a.html">Clinical Utility Gene Card</ext-link> [<xref ref-type="bibr" rid="oca4.REF.gr_nskov.2014.22">Gr&#x000f8;nskov et al 2014</xref>] for information on test characteristics including sensitivity and specificity.</p>
        </sec>
      </sec>
      <sec id="oca4.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="oca4.Clinical_Description">
          <title>Clinical Description</title>
          <p>A wide range of clinical phenotypes has been recognized to date [<xref ref-type="bibr" rid="oca4.REF.suzuki.2008.1">Suzuki &#x00026; Tomita 2008</xref>]. The amount of cutaneous pigmentation in OCA4 is a continuum from minimal to near normal [<xref ref-type="bibr" rid="oca4.REF.newton.2001.981">Newton et al 2001</xref>, <xref ref-type="bibr" rid="oca4.REF.inagaki.2004.466">Inagaki et al 2004</xref>, <xref ref-type="bibr" rid="oca4.REF.rundshagen.2004.106">Rundshagen et al 2004</xref>, <xref ref-type="bibr" rid="oca4.REF.ikinciogullari.2005.177">Ikinciogullari et al 2005</xref>, <xref ref-type="bibr" rid="oca4.REF.inagaki.2005.385">Inagaki et al 2005</xref>]. The amount of iris and retinal pigment varies and visual acuity covers a wide range; however, no subtypes of OCA4 are recognized.</p>
          <p>Individuals with albinism (including OCA4) are usually recognized within the first year of life because of the ocular features of nystagmus and strabismus. In many families, particularly in those with darker constitutional pigmentation, the cutaneous hypopigmentation is also obvious at birth and suggests the diagnosis.</p>
          <sec id="oca4.Eye">
            <title>Eye</title>
            <p><bold>Nystagmus.</bold> Some children with albinism have nystagmus that is noticed by the parents and the examining physician in the delivery room. Many children with albinism do not have nystagmus at birth and the parents note slow wandering eye movements and a lack of visual attention. The parents may become concerned because the child does not seem to "focus well," but the absence of nystagmus may delay the diagnosis. Most children with albinism develop nystagmus by age three to four months, and the diagnosis is often considered at the four-to-six month well-baby check-up. The nystagmus can be rapid early in life and generally slows with time; however, nearly all individuals with albinism have nystagmus throughout their lives. Nystagmus is more noticeable when individuals are tired, angry, or anxious, and less marked when they are well rested and feeling well [<xref ref-type="bibr" rid="oca4.REF.summers.2009.659">Summers 2009</xref>].</p>
            <p><bold>Iris color</bold> ranges from blue to brown. In one individual with OCA4, who had been misdiagnosed at birth as having OCA1 because of complete iris transillumination, the amount of iris pigment increased in the first ten years, resulting in blue iris color [<xref ref-type="bibr" rid="oca4.REF.suzuki.2005.174">Suzuki et al 2005</xref>].</p>
            <p><bold>Visual acuity</bold> in individuals with OCA4 ranges from 20/30 to 20/400 and is usually in the range of 20/100 to 20/200 [<xref ref-type="bibr" rid="oca4.REF.rundshagen.2004.106">Rundshagen et al 2004</xref>, <xref ref-type="bibr" rid="oca4.REF.suzuki.2005.174">Suzuki et al 2005</xref>]. Vision is likely to be stable after early childhood and no major change or further reduction in vision should occur; loss of vision later in life is generally not related to the albinism.</p>
          </sec>
          <sec id="oca4.HairSkin">
            <title>Hair/Skin</title>
            <p>The range of hair and skin pigment in individuals with OCA4 is broad [<xref ref-type="bibr" rid="oca4.REF.newton.2001.981">Newton et al 2001</xref>, <xref ref-type="bibr" rid="oca4.REF.inagaki.2004.466">Inagaki et al 2004</xref>, <xref ref-type="bibr" rid="oca4.REF.rundshagen.2004.106">Rundshagen et al 2004</xref>, <xref ref-type="bibr" rid="oca4.REF.ikinciogullari.2005.177">Ikinciogullari et al 2005</xref>, <xref ref-type="bibr" rid="oca4.REF.inagaki.2005.385">Inagaki et al 2005</xref>].</p>
            <p><bold>Hair.</bold> Individuals with OCA4 are often born with some pigment in their hair that ranges in color from silvery white to light yellow.</p>
            <list list-type="bullet">
              <list-item>
                <p>Scalp hair may be very light, but it is usually not completely white (not as white as a sheet of paper or fresh snow); some parents may refer to light yellow/blond hair color as "white" or "nearly white" if it is very lightly pigmented or is much lighter than the hair color of other family members at a similar age.</p>
              </list-item>
              <list-item>
                <p>Furthermore, the definition of "white" scalp hair is not easy in some young children because the hair may be sparse and short and because some shampoos discolor hair.</p>
              </list-item>
              <list-item>
                <p>It is helpful to hold a piece of white paper next to the hair to determine if it is truly white.</p>
              </list-item>
              <list-item>
                <p>Hair color may darken with time, but usually the hair color does not change dramatically between childhood and adulthood [<xref ref-type="bibr" rid="oca4.REF.inagaki.2004.466">Inagaki et al 2004</xref>].</p>
              </list-item>
            </list>
            <p><bold>Skin.</bold> When hair color is blond or yellow, the skin is usually creamy white with little or no pigmentation. When hair color is somewhat darker, the skin is usually similar to that seen in unaffected individuals [<xref ref-type="bibr" rid="oca4.REF.thody.1991.340">Thody et al 1991</xref>].</p>
            <p>Skin color in individuals with OCA4 is not usually as white as that in individuals with the OCA1A subtype of oculocutaneous albinism type 1, reflecting the fact that skin melanocytes in individuals with OCA4 can still synthesize some melanin; however, the majority of the melanin is yellow pheomelanin rather than black-brown eumelanin.</p>
            <p><bold>Skin cancer risk.</bold> Over many years, exposure of lightly pigmented skin to the sun can result in coarse, rough, thickened skin (pachydermia), solar keratoses (premalignant lesions), and skin cancer. Both basal cell carcinoma and squamous cell carcinoma can develop. The incidence rate of melanoma in individuals with OCA is unknown; however, the risk for melanoma in this population is generally considered to be higher than in unaffected individuals [<xref ref-type="bibr" rid="oca4.REF.streutker.2000.149">Streutker et al 2000</xref>, <xref ref-type="bibr" rid="oca4.REF.asuquo.2009.636">Asuquo et al 2009</xref>].</p>
            <p>Skin cancer is unusual in individuals with OCA4 in the US because of the availability of sunscreens, the social acceptability of wearing clothes that cover most of the exposed skin, and the fact that individuals with albinism often do not spend a great deal of time outside in the sun. Skin cancer in an individual with any type of OCA is very rare in northern areas of the US. Skin cancer in individuals with albinism is common particularly in some parts of Africa because of the increased amount of sun exposure throughout the year, the cultural differences in protective dress, and lack of skin-protective agents such as sunscreens. In addition, African individuals with albinism tend to have poorer prognosis with skin cancer because of late presentation to care and failure to complete treatment for economic reasons [<xref ref-type="bibr" rid="oca4.REF.mabula.2012.5">Mabula et al 2012</xref>].</p>
          </sec>
        </sec>
        <sec id="oca4.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>The lack of a functional assay for the <italic toggle="yes">SLC45A2</italic> protein and the limited data from <italic toggle="yes">SLC45A2</italic> molecular genetic testing make genotype-phenotype correlations difficult [<xref ref-type="bibr" rid="oca4.REF.newton.2001.981">Newton et al 2001</xref>, <xref ref-type="bibr" rid="oca4.REF.rundshagen.2004.106">Rundshagen et al 2004</xref>, <xref ref-type="bibr" rid="oca4.REF.ikinciogullari.2005.177">Ikinciogullari et al 2005</xref>, <xref ref-type="bibr" rid="oca4.REF.inagaki.2005.385">Inagaki et al 2005</xref>, <xref ref-type="bibr" rid="oca4.REF.konno.2009.1773">Konno et al 2009</xref>].</p>
          <p>Two common pathogenic alleles, <xref ref-type="sec" rid="oca4.References">p.Asp157Asn</xref> and <xref ref-type="sec" rid="oca4.References">p.Gly188Val</xref>, have been reported in Japanese individuals. The p.Asp157Asn allele may have very low functional activity in melanogenesis; p.Gly188Val may have some residual functional activity [<xref ref-type="bibr" rid="oca4.REF.inagaki.2004.466">Inagaki et al 2004</xref>].</p>
          <p>Recently, a family with autosomal dominant OCA4 has been reported [<xref ref-type="bibr" rid="oca4.REF.oki.2017.1008">Oki et al 2017</xref>], with a novel heterozygous pathogenic variant: <xref ref-type="table" rid="oca4.T.slc45a2_pathogenic_variants_discu">c.208T&#x0003e;C</xref> (p.Tyr70His). Family members with the variant demonstrate a relatively mild phenotype, with a slightly creamy complexion, brown to black hair, and mild iris hypopigmentation.</p>
          <p>The degree of cutaneous pigmentation, ocular pigmentation, and visual development resulting from particular <italic toggle="yes">SLC45A2</italic> pathogenic variants cannot be predicted at this time.</p>
        </sec>
        <sec id="oca4.Nomenclature">
          <title>Nomenclature</title>
          <p>The ocular features of all types of oculocutaneous albinism (OCA) and <related-object link-type="booklink" source-id="gene" document-id="x-oa" document-type="chapter">X-linked ocular albinism</related-object> (OA1) are similar and the terms "oculocutaneous albinism" and "albinism" can be used interchangeably when referring to these clinical features.</p>
        </sec>
        <sec id="oca4.Prevalence">
          <title>Prevalence</title>
          <p>Prevalence of OCA4 is thought to be on the order of 1:100,000 in most populations throughout the world. It is likely to be more common in Japan, where it accounts for 24% of individuals with OCA [<xref ref-type="bibr" rid="oca4.REF.inagaki.2004.466">Inagaki et al 2004</xref>, <xref ref-type="bibr" rid="oca4.REF.inagaki.2005.385">Inagaki et al 2005</xref>].</p>
          <p>OCA4 has also been described in individuals of German, Turkish, Korean, Indian, Chinese, Danish, and Moroccan descent [<xref ref-type="bibr" rid="oca4.REF.newton.2001.981">Newton et al 2001</xref>, <xref ref-type="bibr" rid="oca4.REF.rundshagen.2004.106">Rundshagen et al 2004</xref>, <xref ref-type="bibr" rid="oca4.REF.ikinciogullari.2005.177">Ikinciogullari et al 2005</xref>, <xref ref-type="bibr" rid="oca4.REF.suzuki.2005.174">Suzuki et al 2005</xref>, <xref ref-type="bibr" rid="oca4.REF.sengupta.2007.1406">Sengupta et al 2007</xref>, <xref ref-type="bibr" rid="oca4.REF.gr_nskov.2009.1058">Gr&#x000f8;nskov et al 2009</xref>, <xref ref-type="bibr" rid="oca4.REF.konno.2009.1773">Konno et al 2009</xref>].</p>
        </sec>
      </sec>
      <sec id="oca4.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>OCA4 is the only phenotype known to be associated with pathogenic variants in <italic toggle="yes">SLC45A2</italic>.</p>
      </sec>
      <sec id="oca4.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <table-wrap id="oca4.T.disorders_to_consider_in_the_diff" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p>Disorders to Consider in the Differential Diagnosis of OCA4</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1">Disorder</th>
                <th id="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2">Gene(s)</th>
                <th id="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3">MOI</th>
                <th id="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Clinical Features of This Disorder</th>
              </tr>
              <tr>
                <th headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4" id="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Overlapping w/OCA4</th>
                <th headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4" id="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Distinguishing from OCA4</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="oca1" document-type="chapter">OCA1</related-object>
                </td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">TYR</italic>
                </td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Oculocutaneous albinism</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">May have poorer visual acuity</td>
              </tr>
              <tr>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="oca2" document-type="chapter">OCA2</related-object>
                </td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">OCA2</italic>
                </td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Oculocutaneous albinism</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
              </tr>
              <tr>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">OCA3<break/>(OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/203290">203290</ext-link>)</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">TYRP1</italic>
                </td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Oculocutaneous albinism</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Reddish hair &#x00026; freckled skin; only described in individuals from African, Pakistani, German, Indian, &#x00026; Japanese populations</td>
              </tr>
              <tr>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">OCA5<break/>(OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/615312">615312</ext-link>)</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown (candidate region is on 4q24)</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Oculocutaneous albinism</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Golden hair</td>
              </tr>
              <tr>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">OCA6<break/>(OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/113750">113750</ext-link>)</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">SLC24A2</italic>
                </td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Oculocutaneous albinism</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Indistinguishable because of the functional similarity of <italic toggle="yes">SLC45A2</italic> (OCA4) and <italic toggle="yes">SLC24A2</italic></td>
              </tr>
              <tr>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">OCA7<break/>(OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/615179">615179</ext-link>)</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">C10orf11</italic>
                </td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Oculocutaneous albinism</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Relatively severe impaired visual acuity</td>
              </tr>
              <tr>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="hps" document-type="chapter">Hermansky-Pudlak syndrome</related-object> (HPS)</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><italic toggle="yes">HPS1</italic><break/><italic toggle="yes">AP3B1</italic> (<italic toggle="yes">HPS2</italic>)<break/><italic toggle="yes">HPS3</italic><break/><italic toggle="yes">HPS4</italic><break/><italic toggle="yes">HPS5</italic><break/><italic toggle="yes">HPS6</italic><break/><italic toggle="yes">DTNBP1</italic> (<italic toggle="yes">HPS7</italic>)<break/><italic toggle="yes">BLOC1S3</italic> (<italic toggle="yes">HPS8</italic>)<break/><italic toggle="yes">BLOC1S6</italic> (<italic toggle="yes">PLDN</italic>)<break/>HPS10</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Oculocutaneous albinism</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Bleeding tendency, platelet dense granules; granulomatous colitis &#x00026; interstitial pneumonia in HPS1 and HPS4; immunodeficiency &#x00026; hemophagocytic syndrome in HPS2 &#x00026; HPS10</td>
              </tr>
              <tr>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="x-oa" document-type="chapter">OA1</related-object>
                </td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">GPR143</italic>
                </td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">XL</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Ocular albinism</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Hypopigmentation of skin &#x00026; hair</td>
              </tr>
              <tr>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="xl-nystag" document-type="chapter"><italic toggle="yes">FRMD7</italic>-related infantile nystagmus</related-object>
                </td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">FRMD7</italic>
                </td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">XL</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Nystagmus</td>
                <td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Oculocutaneous albinism</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>MOI = mode of inheritance</p>
            </fn>
            <fn>
              <p>AD = autosomal dominant</p>
            </fn>
            <fn>
              <p>AR = autosomal recessive</p>
            </fn>
            <fn>
              <p>XL = X-linked</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="oca4.Management">
        <title>Management</title>
        <sec id="oca4.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with oculocutaneous albinism type 4 (OCA4), the following evaluations are recommended if they have not already been completed:</p>
          <list list-type="bullet">
            <list-item>
              <p>Complete ophthalmologic evaluation including measurement of visual acuity and refractive error</p>
            </list-item>
            <list-item>
              <p>Assessment for strabismus</p>
            </list-item>
            <list-item>
              <p>Assessment by dermatologist to instruct parents regarding use of sun-protective clothing, lotions, and formulas</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="oca4.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Ophthalmologic care is the most important part of the ongoing care for most individuals with OCA4.</p>
          <p>The majority of individuals with albinism have significant hyperopia or myopia and astigmatism. Correction of these refractive errors with spectacles or contact lenses can improve visual acuity. Except in the very unusual individual, correction of refractive errors cannot restore visual acuity to normal because of the foveal hypoplasia.</p>
          <p>The alternating strabismus found in most individuals with albinism is generally not associated with the development of amblyopia. Strabismus surgery is usually not required, but can be considered for cosmetic reasons if the strabismus is marked or fixed.</p>
          <p>Photophobia is common in individuals with OCA4, but the degree of discomfort varies and does not depend entirely on the amount of melanin pigment present in the iris or skin. In general, opaque contact lenses or darkly tinted lenses do not improve visual function. Dark glasses may be helpful for individuals with albinism, but many prefer to go without dark glasses because of the reduction in vision from the dark lenses. A hat with a brim (e.g., a baseball hat with a visor) is often the best way to achieve reduction in photophobia and sun protection.</p>
          <p>Protection from the sun through the wearing of protective clothing and the regular application of sunscreen is essential to prevent sunburn and secondary skin changes, and to decrease the risk of skin cancer in later life. Regular skin check-ups for skin cancer are recommended for adult individuals with OCA4, especially in cases of severe hypopigmentation.</p>
        </sec>
        <sec id="oca4.Prevention_of_Secondary_Complicatio">
          <title>Prevention of Secondary Complications</title>
          <p>Individuals with OCA4 should stay out of the sun from an early age, as cumulative ultraviolet exposure is a major risk factor for skin cancers (see <xref ref-type="sec" rid="oca4.HairSkin">Skin Cancer Risk</xref>).</p>
          <p>Prolonged periods in the sun require skin protection with clothing (hats with brims, long sleeves and pants, socks) and sunscreen with a high SPF number (total blocks with SPF 45-50+). There is no scientific evidence to indicate how high an SPF value is enough; individuals with OCA4 should use sunscreen with higher SPF values (45-50+) to lessen as much as possible the cumulative effect of ultraviolet to their skin.</p>
        </sec>
        <sec id="oca4.Surveillance">
          <title>Surveillance</title>
          <p>Annual ophthalmologic examination and reassessment for accurate correction of refractive error are appropriate.</p>
          <p>There is no definitive guideline supported by scientific evidence as to how often an individual should be evaluated by a dermatologist, though an evaluation of the skin for cancer screening every six months is recommended.</p>
        </sec>
        <sec id="oca4.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoid prolonged exposure of the skin to the sun.</p>
        </sec>
        <sec id="oca4.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="oca4.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="oca4.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="oca4.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="oca4.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>OCA4 is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="oca4.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected individual are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">SLC45A2</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and not at risk of developing the disorder; they may be light in pigmentation for their ethnic group.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder, although they may be light in pigmentation for their ethnic group.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Unless an individual with OCA4 has children with an affected individual or a carrier, his/her offspring will be obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">SLC45A2</italic>.</p>
          <p><bold>Other family members.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier of a <italic toggle="yes">SLC45A2</italic> pathogenic variant.</p>
        </sec>
        <sec id="oca4.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">SLC45A2</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="oca4.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="oca4.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">SLC45A2</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible.</p>
          <p>A fetal skin biopsy will not provide an accurate diagnosis and is not appropriate for prenatal diagnosis of OCA4.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="oca4.Resources">
        <title>Resources</title>
      </sec>
      <sec id="oca4.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="oca4.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>The phenotype resulting from heterozygosity of a single <italic toggle="yes">Slc45a2</italic> pathogenic variant in mice results in hypopigmentation that may be analogous to some of the autosomal dominant forms of albinism reported in humans. Apparent autosomal dominant inheritance of OCA4 has been recently reported in a single Japanese family [<xref ref-type="bibr" rid="oca4.REF.oki.2017.1008">Oki et al 2017</xref>].</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">SLC45A2</italic> has seven exons and spans 40 kb at chromosome 5p13.3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_016180.3">NM_016180.3</ext-link>).</p>
          <p><bold>Pathogenic variants.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://albinism.med.umn.edu/">International Albinism home page</ext-link>. Fifty-three pathogenic variants of <italic toggle="yes">SLC45A2</italic> have been reported. Most are missense variants, but deletions of one or a small number of bases and base changes have been detected [<xref ref-type="bibr" rid="oca4.REF.newton.2001.981">Newton et al 2001</xref>, <xref ref-type="bibr" rid="oca4.REF.inagaki.2004.466">Inagaki et al 2004</xref>, <xref ref-type="bibr" rid="oca4.REF.rundshagen.2004.106">Rundshagen et al 2004</xref>, <xref ref-type="bibr" rid="oca4.REF.ikinciogullari.2005.177">Ikinciogullari et al 2005</xref>, <xref ref-type="bibr" rid="oca4.REF.inagaki.2005.385">Inagaki et al 2005</xref>, <xref ref-type="bibr" rid="oca4.REF.suzuki.2005.174">Suzuki et al 2005</xref>, <xref ref-type="bibr" rid="oca4.REF.sengupta.2007.1406">Sengupta et al 2007</xref>, <xref ref-type="bibr" rid="oca4.REF.gr_nskov.2009.1058">Gr&#x000f8;nskov et al 2009</xref>, <xref ref-type="bibr" rid="oca4.REF.konno.2009.1773">Konno et al 2009</xref>]. The most common <italic toggle="yes">SLC45A2</italic> pathogenic variant in Japanese individuals, accounting for 39% of pathogenic alleles, is the p.Asp157Asn missense variant [<xref ref-type="bibr" rid="oca4.REF.inagaki.2004.466">Inagaki et al 2004</xref>].</p>
          <p>Most individuals with OCA4 are compound heterozygotes for <italic toggle="yes">SLC45A2</italic> pathogenic variants. Approximately 17% of reported Japanese individuals and a cohort from India have only one identifiable pathogenic variant; the second variant could not be detected with the methods used [<xref ref-type="bibr" rid="oca4.REF.inagaki.2004.466">Inagaki et al 2004</xref>, <xref ref-type="bibr" rid="oca4.REF.sengupta.2007.1406">Sengupta et al 2007</xref>]. (For more information, see <related-object source-id="gene" document-id="oca4" object-id="oca4.molgen.TA">Table A</related-object>.).</p>
          <table-wrap id="oca4.T.slc45a2_pathogenic_variants_discu" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p><italic toggle="yes">SLC45A2</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                  <th id="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.208T&#x0003e;C</td>
                  <td headers="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr70His</td>
                  <td headers="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_016180.3">NM_016180.3</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_057264.3">NP_057264.3</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.469G&#x0003e;A</td>
                  <td headers="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asp157Asn</td>
                </tr>
                <tr>
                  <td headers="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.563G&#x0003e;T</td>
                  <td headers="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly188Val</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> The MATP protein consists of 530 amino acids, contains 12 transmembrane domains, and is only expressed in mealocytes (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_057264.3">NP_057264.3</ext-link>) [<xref ref-type="bibr" rid="oca4.REF.newton.2001.981">Newton et al 2001</xref>]. The precise function of the MATP protein is yet to be elucidated, although it appears to play a role in tyrosinase processing, intracellular trafficking of tyrosinase to melanosome, and regulating tyrosinase activity through controlling melanomal pH [<xref ref-type="bibr" rid="oca4.REF.costin.2003.3203">Costin et al 2003</xref>, <xref ref-type="bibr" rid="oca4.REF.bin.2015.e0129273">Bin et al 2015</xref>].</p>
          <p><bold>Abnormal gene product.</bold> The mechanisms by which the abnormal protein alters the ability of the cell to synthesize melanin are unknown. However, tyrosinase, the rate-limiting enzyme in the biosynthesis of melanin that is associated with OCA1, appears to be mislocalized in mouse melanocytes that are homozygous for pathogenic <italic toggle="yes">SLC45A2</italic> alleles [<xref ref-type="bibr" rid="oca4.REF.costin.2003.3203">Costin et al 2003</xref>]. This phenotype is shared with melanocytes that contain pathogenic variants in <italic toggle="yes">OCA2</italic>, the gene associated with <related-object link-type="booklink" source-id="gene" document-id="oca2" document-type="chapter">OCA2</related-object> [<xref ref-type="bibr" rid="oca4.REF.toyofuku.2002.217">Toyofuku et al 2002</xref>].</p>
        </sec>
      </sec>
      <sec id="oca4.References">
        <title>References</title>
        <sec id="oca4.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="oca4.Literature_Cited.reflist0">
            <ref id="oca4.REF.asuquo.2009.636">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Asuquo</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ngim</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ebughe</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bassey</surname>
                    <given-names>EE</given-names>
                  </name>
                </person-group>
                <article-title>Skin cancers amongst four Nigerian albinos.</article-title>
                <source>Int J Dermatol.</source>
                <year>2009</year>
                <volume>48</volume>
                <fpage>636</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19538377</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.bin.2015.e0129273">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bin</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nam</surname>
                    <given-names>YJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choi</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shin</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>AY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwang</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cho</surname>
                    <given-names>EG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>TR</given-names>
                  </name>
                </person-group>
                <article-title>Membrane-Associated Transporter Protein (MATP) regulates melanosomal pH and influences tyrosinase activity.</article-title>
                <source>PLoS One.</source>
                <year>2015</year>
                <volume>10</volume>
                <fpage>e0129273</fpage>
                <pub-id pub-id-type="pmid">26057890</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.costin.2003.3203">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Costin</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valencia</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vieira</surname>
                    <given-names>WD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamoreux</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hearing</surname>
                    <given-names>VJ</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Tyrosinase processing and intracellular trafficking is disrupted in mouse primary melanocytes carrying the underwhite (uw) mutation. A model for oculocutaneous albinism (OCA) type 4.</article-title>
                <source>J Cell Sci</source>
                <volume>116</volume>
                <fpage>3203</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">12829739</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.gr_nskov.2009.1058">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gr&#x000f8;nskov</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ek</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sand</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheller</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bygum</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brixen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brondum-Nielsen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Birth prevalence and mutation spectrum in Danish patients with autosomal recessive albinism.</article-title>
                <source>Invest Ophthalmol Vis Sci</source>
                <volume>50</volume>
                <fpage>1058</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">19060277</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.gr_nskov.2014.22">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gr&#x000f8;nskov</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Br&#x000f8;ndum-Nielsen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorenz</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Preising</surname>
                    <given-names>MN</given-names>
                  </name>
                </person-group>
                <article-title>Clinical utility gene card for: oculocutaneous albinism.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2014</year>
                <fpage>22</fpage>
                <pub-id pub-id-type="pmid">24713663</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.hutton.2008.2442">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hutton</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spritz</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>Comprehensive analysis of oculocutaneous albinism among non-Hispanic caucasians shows that OCA1 is the most prevalent OCA type.</article-title>
                <source>J Invest Dermatol.</source>
                <year>2008</year>
                <volume>128</volume>
                <fpage>2442</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">18463683</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.ikinciogullari.2005.177">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ikinciogullari</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tekin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dogu</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reisli</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanir</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yi</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garrison</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brilliant</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Babacan</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Meningococccal meningitis and complement component 6 deficiency associated with oculocutaneous albinism.</article-title>
                <source>Eur J Pediatr</source>
                <volume>164</volume>
                <fpage>177</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15565285</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.inagaki.2005.385">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Inagaki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukai</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horiuchi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manabe</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomita</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>OCA4: evidence for a founder effect for the p.D157N mutation of the MATP gene in Japanese and Korean.</article-title>
                <source>Pigment Cell Res.</source>
                <volume>18</volume>
                <fpage>385</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16162179</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.inagaki.2004.466">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Inagaki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishii</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Umezawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tada</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kikuchi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takata</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takamori</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishibe</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyamura</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomita</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Oculocutaneous albinism type 4 is one of the most common types of albinism in Japan.</article-title>
                <source>Am J Hum Genet</source>
                <volume>74</volume>
                <fpage>466</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">14961451</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.konno.2009.1773">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Konno</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abe</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawaguchi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Storm</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biervliet</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Courtens</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kono</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomita</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>T.</given-names>
                  </name>
                </person-group>
                <article-title>Oculocutaneous albinism type IV: A boy of Moroccan descent with a novel mutation in SLC45A2.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2009</year>
                <volume>149A</volume>
                <fpage>1773</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19610114</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.mabula.2012.5">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mabula</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chalya</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mchembe</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giiti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rambau</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masalu</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamugisha</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robert</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilyoma</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <article-title>Skin cancers among Albinos at a university teaching hospital in Northwestern Tanzania: a retrospective review of 64 cases.</article-title>
                <source>BMC Dermatol.</source>
                <year>2012</year>
                <volume>12</volume>
                <fpage>5</fpage>
                <pub-id pub-id-type="pmid">22681652</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.mauri.2017.277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mauri</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manfredini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Del Longo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veniani</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scarcello</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terrana</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Radaelli</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cal&#x000f2;</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mingoia</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossetti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsico</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazza</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gesu</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cristina Patrosso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penco</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piozzi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Primignani</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Clinical evaluation and molecular screening of a large consecutive series of albino patients.</article-title>
                <source>J Hum Genet.</source>
                <year>2017</year>
                <volume>62</volume>
                <fpage>277</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">27734839</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.newton.2001.981">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Newton</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen-Barak</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagiwara</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gardner</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davisson</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brilliant</surname>
                    <given-names>MH</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Mutations in the human orthologue of the mouse underwhite gene (uw) underlie a new form of oculocutaneous albinism, OCA4.</article-title>
                <source>Am J Hum Genet</source>
                <volume>69</volume>
                <fpage>981</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11574907</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.oki.2017.1008">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Oki</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kubota</surname>
                    <given-names>T.</given-names>
                  </name>
                </person-group>
                <article-title>A Japanese family with autosomal dominant oculocutaneous albinism type 4.</article-title>
                <source>Invest Ophthalmol Vis Sci.</source>
                <year>2017</year>
                <volume>58</volume>
                <fpage>1008</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">28192564</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.rooryck.2008.583">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rooryck</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morice-Picard</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elcioglu</surname>
                    <given-names>NH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taieb</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arveiler</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Molecular diagnosis of oculocutaneous albinism: new mutations in the OCA1-4 genes and practical aspects.</article-title>
                <source>Pigment Cell Melanoma Res</source>
                <volume>21</volume>
                <fpage>583</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18821858</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.rundshagen.2004.106">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rundshagen</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zuhlke</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opitz</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwinger</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kasmann-Kellner</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Mutations in the MATP gene in five German patients affected by oculocutaneous albinism type 4.</article-title>
                <source>Hum Mutat</source>
                <volume>23</volume>
                <fpage>106</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">14722913</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.sengupta.2007.1406">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sengupta</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arti</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ray</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>SLC45A2 variations in Indian oculocutaneous albinism patients.</article-title>
                <source>Mol Vis</source>
                <volume>13</volume>
                <fpage>1406</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">17768386</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.streutker.2000.149">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Streutker</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCready</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jimbow</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>From</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>Malignant melanoma in a patient with oculocutaneous albinism.</article-title>
                <source>J Cutan Med Surg.</source>
                <year>2000</year>
                <volume>4</volume>
                <fpage>149</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">11003720</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.summers.2009.659">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Summers</surname>
                    <given-names>CG</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Albinism: classification, clinical characteristics, and recent findings.</article-title>
                <source>Optom Vis Sci</source>
                <volume>86</volume>
                <fpage>659</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">19390472</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.suzuki.2005.174">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inagaki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukai</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Obana</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomita</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>A Korean case of oculocutaneous albinism type IV caused by a D157N mutation in the MATP gene.</article-title>
                <source>Br J Dermatol.</source>
                <volume>152</volume>
                <fpage>174</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15656822</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.suzuki.2008.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomita</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Recent advances in genetic analyses of oculocutaneous albinism types 2 and 4.</article-title>
                <source>J Dermatol Sci.</source>
                <year>2008</year>
                <volume>51</volume>
                <fpage>1</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18407468</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.thody.1991.340">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thody</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Higgins</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wakamatsu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burchill</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marks</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <article-title>Pheomelanin as well as eumelanin is present in human epidermis.</article-title>
                <source>J Invest Dermatol.</source>
                <year>1991</year>
                <volume>97</volume>
                <fpage>340</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">2071942</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.toyofuku.2002.217">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Toyofuku</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valencia</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kushimoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costin</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Virador</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vieira</surname>
                    <given-names>WD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrans</surname>
                    <given-names>VJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hearing</surname>
                    <given-names>VJ</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>The etiology of oculocutaneous albinism (OCA) type II: the pink protein modulates the processing and transport of tyrosinase.</article-title>
                <source>Pigment Cell Res</source>
                <volume>15</volume>
                <fpage>217</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">12028586</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.wei.2011.124">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lian</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <article-title>Implementation of an optimized strategy for genetic testing of the Chinese patients with oculocutaneous albinism.</article-title>
                <source>J Dermatol Sci.</source>
                <year>2011</year>
                <volume>62</volume>
                <fpage>124</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21458243</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="oca4.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="oca4.Suggested_Reading.reflist0">
            <ref id="oca4.REF.konno.2009.235">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Konno</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abe</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawaguchi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomita</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Functional analysis of OCA4 mutant sequences using under white mouse melanocytes.</article-title>
                <source>Pigment Cell Melanoma Res</source>
                <volume>22</volume>
                <fpage>235</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19220778</pub-id>
              </element-citation>
            </ref>
            <ref id="oca4.REF.li.2008.1198">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meng</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zheng</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>A Chinese case of oculocutaneous albinism type 4 with two novel mutations.</article-title>
                <source>Int J Dermatol</source>
                <volume>47</volume>
                <fpage>1198</fpage>
                <lpage>201</lpage>
                <pub-id pub-id-type="pmid">18986462</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="oca4.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="oca4.Author_History">
          <title>Author History</title>
          <p>Murray H Brilliant, PhD; University of Wisconsin School of Medicine (2005-2011)Masahiro Hayashi, MD, PhD (2011-present)Tamio Suzuki, MD, PhD (2011-present)</p>
        </sec>
        <sec id="oca4.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>7 September 2017 (ha) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>15 September 2011 (cd) Revision: deletion/duplication analysis of <italic toggle="yes">SCL45A2</italic> available clinically</p>
            </list-item>
            <list-item>
              <p>5 May 2011 (me) Comprehensive updated posted live</p>
            </list-item>
            <list-item>
              <p>14 June 2007 (cd) Revision: sequence analysis and prenatal diagnosis available clinically</p>
            </list-item>
            <list-item>
              <p>17 November 2005 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>21 April 2005 (mb) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
